Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.

Author: Brajin Taulrajas
Country: Djibouti
Language: English (Spanish)
Genre: Technology
Published (Last): 7 November 2016
Pages: 314
PDF File Size: 19.98 Mb
ePub File Size: 1.30 Mb
ISBN: 874-2-84043-868-1
Downloads: 3924
Price: Free* [*Free Regsitration Required]
Uploader: Dojora

Moderate Drugs that are actively secreted via cationic secretion, such as lamivudine, should be co-administered with dofetilide with caution since they could increase dofetilide plasma concentrations via potential competition for renal tubular secretion.

Dolutegravir inhibits the renal organic cation transporter OCT2, dofetilide is eliminated via this transporter.

Because of the potential for TdP, use of dofetilide with trifluoperazine is contraindicated. Because of the potential for TdP, use of venlafaxine with dofetilide is contraindicated. Severe Insedt should be avoided in patients receiving drugs which may induce QT prolongation; these drugs include class III antiarrhythmics.

John’s wort could decrease the efficacy of some medications metabolized by CYP3A4, such as dofetilide. Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. Coadministration may increase the exposure of dofetilide.

Increases in QTc interval have been observed in healthy volunteers treated with sparfloxacin, and torsade de pointes has been reported in patients receiving sparfloxacin with disopyramide and amiodarone. The manufacturer recommends using actual body weight in the Cockcroft-Gault equation to calculate creatinine clearance.


We’re strengthening digital security to protect you.

Dalfopristin; quinupristin is a weak CYP3A4 inhibitor. Doravirine; Lamivudine; Tenofovir disoproxil fumarate: Moderate Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with amlodipine is necessary. Dofetilide therapy requires an experienced clinician trained in the management pcakage serious ventricular arrhythmias.

Granisetron has been associated with QT prolongation. Severe Because of the potential for torsade de pointes TdPuse of histrelin with dofetilide is contraindicated. Grapefruit juice inhibits the cytochrome P 3A4 isozyme in the gut wall. The terminal half-life is approximately 10 hours, and steady state plasma concentrations are attained within 2 to 3 days.

Send the page ” ” to a friend, relative, colleague or yourself. Major Use caution if dofetilide and aprepitant, fosaprepitant are used concurrently and monitor for an increase in dofetilide-related adverse effects, including QT prolongation and torsade de pointes TdPfor several days after administration of a multi-day aprepitant regimen. Because increases in the QT interval and the risk of ventricular arrhythmias are directly related to plasma concentrations of dofetilide, it is critical that the dose of dofetilide be adjusted based on calculated CrCl.

Major Clinicians should be aware that food interactions with dofetilide are possible. Because of the potential for TdP, use of atomoxetine with dofetilide is contraindicated. Vandetanib can prolong the QT interval in a concentration-dependent manner.


Moderate Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with everolimus is necessary. Because of the potential for TdP, use of fluoxetine with dofetilide is contraindicated. Isavuconazonium inhibits the renal organic cation transporter OCT2, and dofetilide is eliminated via this transporter.

Halogenated anesthetics can prolong the QT interval. Lamotrigine is an inhibitor of renal tubular secretion via organic cationic transporter 2 OCT2 proteins, and dofetilide is excreted via this route.

Because of the potential for TdP, dofetilide is contraindicated with any drug associated with QT prolongation. Before switching from another antiarrhythmic drug to dofetilide therapy, antiarrhythmics generally should be withheld for at least three half-lives prior to initiating dofetilide.

Erythromycin administration is associated with QT prolongation and TdP. In addition, monitor patients receiving lacosamide via the intravenous route closely.

Tikosyn (dofetilide) dose, indications, adverse effects, interactions from

Entecavir is also excreted via renal tubular excretion. No dosage adjustment is needed for patients with mild to moderate hepatic impairment. Women should be advised to discontinue dodetilide an infant while taking dofetilide. John’s wort is used. It is theoretically possible that ginger could affect the action of antiarrhythmics, however, no human data are available.